Antibody response to SARS-CoV-2 is stronger and more durable in infants and young children Antibody Coronavirus Disease COVID SARSCoV2 medrxivpreprint EmoryMedicine EmoryUniversity uofcincy
By Tarun Sai LomteApr 15 2023Reviewed by Lily Ramsey, LLM In a recent study on the medRxiv* preprint server, researchers evaluated humoral responses to severe acute respiratory syndrome coronavirus 2 in infants.
Still, immune responses in infants and young children are poorly defined. Although one in every four infected infants is asymptomatic, severe illness is more prevalent in infants than older children. Adults with confirmed coronavirus disease 2019 were followed up until 350 days post-infection. Most adults did not require hospitalization, and no adult patient developed severe symptoms.
Related StoriesFurther, the researchers noted that the pre-existing antibodies against common human CoVs did not impact the antibody responses against SARS-CoV-2. Most infants and adults exhibited measurable nAb titers. The nAb titers were comparable between cohorts' early points .
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study suggests detecting new SARS-CoV-2 variants in inbound travelers more effective than community surveillanceStudy suggests detecting new SARS-CoV-2 variants in inbound travelers more effective than community surveillance Coronavirus Disease COVID SARSCoV2 medrxivpreprint
Read more »
Study finds no association between maternal SARS-CoV-2 infection and infant neurodevelopmentStudy finds no association between maternal SARS-CoV-2 infection and infant neurodevelopment Coronavirus COVID neurodevelopment infanthealth telehealthassessment observationalstudy publichealth maternalhealth asymptomatic JAMANetworkOpen
Read more »
Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report - npj VaccinesOn November 7th and 8th, 2022, The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), The Coalition for Epidemic Preparedness Innovation (CEPI), The Bill & Melinda Gates Foundation (BMGF), The Biomedical Advanced Research and Development Authority (BARDA), and the Wellcome Trust hosted a virtual workshop entitled “Mucosal Vaccines for SARS-CoV-2: Scientific Gaps and Opportunities.” During the workshop, researchers and vaccine developers from around the world discussed the potential of mucosal vaccines to block SARS-CoV-2 transmission and reviewed the status of SARS-CoV-2 mucosal vaccine research. Here, we summarize key challenges and opportunities in basic, translational, and clinical research that were highlighted during the meeting. We also provide recommendations to advance the field and accelerate the development of mucosal vaccines for SARS-CoV-2.
Read more »
How SARS-CoV-2 Omicron subvariants have evolved to evade host T-cell immunityHow SARS-CoV-2 Omicron subvariants have evolved to evade host T-cell immunity SARSCoV2 COVID19 OmicronVariant Tcell MHC1 immunesystem virology research PNASNews Yale
Read more »
Frontiers | DNA immunization with in silico predicted T-cell epitopes protects against lethal SARS-CoV-2 infection in K18-hACE2 miceThe global SARS-CoV-2 pandemic caused significant global disruption, both socially and economically, despite highly effective vaccines being developed at an unprecedented speed. As the first licensed vaccines only target single B-cell antigens, antigenic drift could lead to loss of efficacy against emerging SARS-CoV-2 variants. Improvement of the B-cell vaccines by including multiple T-cell epitopes could potentially solve this challenge. Here we show that in silico predicted MHC class I/II ligands induced robust T-cell responses and protected against severe disease in genetically modified K18-hACE2/BL6 mice susceptible to SARS-CoV-2 infection.
Read more »
Researchers assemble comprehensive atlas of gene mutations in human tissueResearchers have created the largest atlas of post-zygotic genome mutations in healthy human tissue ever assembled—a scientific advancement that could unlock new avenues for diagnosing and treating genetic disease. It is the largest ever in terms of the combined number of tissues and number of donors sampled.
Read more »